Institution
University of Southern Denmark
Education•Odense, Syddanmark, Denmark•
About: University of Southern Denmark is a education organization based out in Odense, Syddanmark, Denmark. It is known for research contribution in the topics: Population & Randomized controlled trial. The organization has 11928 authors who have published 37918 publications receiving 1258559 citations. The organization is also known as: SDU.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The present document updates previous guidelines released in 2006 and 2010 and states that percutaneous ethanol injection should be the first-line treatment option for relapsing, benign cystic lesions, while US-guided thermal ablation treatments may be considered for solid or mixed symptomatic benign thyroid nodules.
898 citations
••
TL;DR: There are lessons to be learned from the current research conducted in countries where the prevalence of bullying is low that could be adapted for use in countries with higher prevalence.
Abstract: Objectives:
(1) To compare the prevalence of bullying and victimization among boys and girls and by age in 40 countries. (2) In 6 countries, to compare rates of direct physical, direct verbal, and indirect bullying by gender, age, and country.
893 citations
••
01 Jan 2008TL;DR: In this article, the authors introduce social network analysis, and present basic methods for analyzing networks, including data collection, basic methods, and advanced methods for analysing networks, such as clustering and clustering.
Abstract: Chapter 1. Introduction to Social Network Analysis Chapter 2. Network Fundamentals Chapter 3. Data Collection Chapter 4. Basic Methods for Analyzing Networks Chapter 5. Advanced Methods for Analyzing Networks References
889 citations
••
TL;DR: Using a cell-free RNA decay system, it is demonstrated that the mammalian exosome is required for rapid degradation of ARE-containing RNAs but not for poly(A) shortening.
884 citations
••
TL;DR: Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma, and no maximum tolerated dose was identified in part 1.
Abstract: BACKGROUND Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1–2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two or more prior lines of therapy. METHODS In part 1, the dose-escalation phase, we administered daratumumab at doses of 0.005 to 24 mg per kilogram of body weight. In part 2, the dose-expansion phase, 30 patients received 8 mg per kilogram of daratumumab and 42 received 16 mg per kilogram, administered once weekly (8 doses), twice monthly (8 doses), and monthly for up to 24 months. End points included safety, efficacy, and pharmacokinetics. RESULTS No maximum tolerated dose was identified in part 1. In part 2, the median time since diagnosis was 5.7 years. Patients had received a median of four prior treatments; 79% of the patients had disease that was refractory to the last therapy received (64% had disease refractory to proteasome inhibitors and immunomodulatory drugs and 64% had disease refractory to bortezomib and lenalidomide), and 76% had received autologous stem-cell transplants. Infusion-related reactions in part 2 were mild (71% of patients had an event of any grade, and 1% had an event of grade 3), with no dose-dependent adverse events. The most common adverse events of grade 3 or 4 (in ≥5% of patients) were pneumonia and thrombocytope nia. The overall response rate was 36% in the cohort that received 16 mg per kilogram (15 patients had a partial response or better, including 2 with a complete response and 2 with a very good partial response) and 10% in the cohort that received 8 mg per kilogram (3 had a partial response). In the cohort that received 16 mg per kilogram, the median progression-free survival was 5.6 months (95% confidence interval [CI], 4.2 to 8.1), and 65% (95% CI, 28 to 86) of the patients who had a response did not have progression at 12 months. CONCLUSIONS Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma. (Funded by Janssen Research and Development and Genmab; ClinicalTrials.gov number, NCT00574288.)
882 citations
Authors
Showing all 12150 results
Name | H-index | Papers | Citations |
---|---|---|---|
Paul M. Ridker | 233 | 1242 | 245097 |
George Davey Smith | 224 | 2540 | 248373 |
Matthias Mann | 221 | 887 | 230213 |
Eric Boerwinkle | 183 | 1321 | 170971 |
Gang Chen | 167 | 3372 | 149819 |
Jun Wang | 166 | 1093 | 141621 |
Harvey F. Lodish | 165 | 782 | 101124 |
Jens J. Holst | 160 | 1536 | 107858 |
Rajesh Kumar | 149 | 4439 | 140830 |
J. Fraser Stoddart | 147 | 1239 | 96083 |
Debbie A Lawlor | 147 | 1114 | 101123 |
Børge G. Nordestgaard | 147 | 1047 | 95530 |
Oluf Pedersen | 135 | 939 | 106974 |
Rasmus Nielsen | 135 | 556 | 84898 |
Torben Jørgensen | 135 | 883 | 86822 |